期刊
NEURAL PLASTICITY
卷 2016, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2016/8501693
关键词
-
资金
- Spanish Ministry of Science and Technology (MCyT project) [MAT2014-59134-R]
- [BES-2012-056083]
Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed countries. There is no effective treatment capable of slowing down disease progression. In recent years the main focus of research on novel pharmacotherapies was based on the amyloidogenic hypothesis of AD, which posits that the beta amyloid (A beta) peptide is chiefly responsible for cognitive impairment and neuronal death. The goal of such treatments is (a) to reduce A beta production through the inhibition of beta and gamma secretase enzymes and (b) to promote dissolution of existing cerebral A beta plaques. However, this approach has proven to be only modestly effective. Recent studies suggest an alternative strategy centred on the inhibition of the downstream A beta signalling, particularly at the synapse. A beta oligomers may cause aberrant N-methyl-D-aspartate receptor (NMDAR) activation postsynaptically by forming complexes with the cell-surface prion protein (PrPC). PrPC is enriched at the neuronal postsynaptic density, where it interacts with Fyn tyrosine kinase. Fyn activation occurs when A beta is bound to PrPC-Fyn complex. Fyn causes tyrosine phosphorylation of the NR2B subunit of metabotropic glutamate receptor 5 (mGluR5). Fyn kinase blockers masitinib and saracatinib have proven to be efficacious in treating AD symptoms in experimental mouse models of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据